Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434648 | 0.87 | TLR8 (0.33) | ALDH1A1HTTKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL855416 | 0.86 | CYP1A2 (0.31) | — | |
| SCHEMBL16461836 | 0.77 | MAPT (0.31) | HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15429642 | 0.77 | — | — | |
| SCHEMBL855415 | 0.76 | — | — | |
| SCHEMBL857230 | 0.76 | SLC6A2 (0.31) | — | |
| SCHEMBL9289682 | 0.75 | ALDH1A1 (0.31) | ALDH1A1TLR8TLR7 | |
| SCHEMBL4980998 | 0.74 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL857121 | 0.74 | PDK2 (0.43) | ALDH1A1HTTKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL9287280 | 0.73 | METAP2 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |